FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741218617> ?p ?o ?g. }

• W2741218617 endingPage "434" @default.
• W2741218617 startingPage "427" @default.
• W2741218617 abstract "Temozolomide is an antineoplastic agent of proven efficacy against high-grade gliomas.The objective of this crossover, single-dose, bioequivalence study was to compare the rate and extent of absorption of oral temozolomide after administration of the study product (Dralitem®, Monte Verde Sociedad Anónima) and the reference product (Temodal®, originator product manufactured by Schering Plough Laboratories) in patients with primary central nervous system (CNS) tumors under fasting conditions.Sixteen male and female subjects with primary CNS tumors (excluding CNS lymphoma) were recruited, and were administered temozolomide 200 mg/m2 (Dralitem®) on days 1, 2 and 5 of a 5-day treatment. On days 3 and 4, subjects received the same dose of the test product (Dralitem®), or the reference product (Temodal®) on alternate days. The single dose of 200 mg/m2 was reached with three different temozolomide capsule strengths: 20, 100 and 250 mg. On days 3 and 4, blood samples were obtained for pharmacokinetic (PK) evaluation after drug administration.Bioequivalence assessment was made for the 90% confidence interval (CI) for the ratio of log-transformed means (μT/μR) of the area under the concentration-time curve (AUC from time zero to the final quantifiable sample [AUCt] and AUC from time zero to infinity [AUC∞]) and maximum concentration (C max) of both the test (Dralitem®) and reference (Temodal®) products. The point estimate and 90% CI of the ratios of C max, AUCt and AUC∞ values were 94.37 (82.69-107.69), 100.99 (97.81-104.28) and 101.53 (98.60-104.54), respectively. The ratio met the predefined bioequivalence criteria (i.e. 90% CI between 80.00 and 125.00) for C max and AUC. The most commonly reported adverse events (AE) on this study were vomiting, abdominal pain, asthenia and weakness. One subject experienced expressive aphasia, possibly unrelated to the study drug and with no significant sequelae upon recovery. No serious AEs or unexpected AEs were reported.Temozolomide Dralitem® capsules, 20, 100 and 250 mg, were bioequivalent to Temodal® capsules under fasting conditions in patients with CNS primary tumors, supporting that they are therapeutic equivalents. ClinicalTrials.gov Identifier: NCT02343081." @default.
• W2741218617 created "2017-08-08" @default.
• W2741218617 creator A5022226107 @default.
• W2741218617 creator A5033535463 @default.
• W2741218617 creator A5042433713 @default.
• W2741218617 creator A5047411615 @default.
• W2741218617 creator A5050945427 @default.
• W2741218617 creator A5058720085 @default.
• W2741218617 creator A5080254894 @default.
• W2741218617 creator A5086263266 @default.
• W2741218617 creator A5089196838 @default.
• W2741218617 date "2017-07-29" @default.
• W2741218617 modified "2023-10-18" @default.
• W2741218617 title "A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® vs. Temodal® Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions" @default.
• W2741218617 cites W1575812451 @default.
• W2741218617 cites W1988417752 @default.
• W2741218617 cites W1990973203 @default.
• W2741218617 cites W1997349871 @default.
• W2741218617 cites W2015346515 @default.
• W2741218617 cites W2051701101 @default.
• W2741218617 cites W2056044064 @default.
• W2741218617 cites W2079203845 @default.
• W2741218617 cites W2079786467 @default.
• W2741218617 cites W2081694393 @default.
• W2741218617 cites W2121205576 @default.
• W2741218617 cites W2129160559 @default.
• W2741218617 cites W2169414079 @default.
• W2741218617 doi "https://doi.org/10.1007/s40268-017-0199-3" @default.
• W2741218617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5629139" @default.
• W2741218617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28756607" @default.
• W2741218617 hasPublicationYear "2017" @default.
• W2741218617 type Work @default.
• W2741218617 sameAs 2741218617 @default.
• W2741218617 citedByCount "5" @default.
• W2741218617 countsByYear W27412186172018 @default.
• W2741218617 countsByYear W27412186172019 @default.
• W2741218617 countsByYear W27412186172020 @default.
• W2741218617 crossrefType "journal-article" @default.
• W2741218617 hasAuthorship W2741218617A5022226107 @default.
• W2741218617 hasAuthorship W2741218617A5033535463 @default.
• W2741218617 hasAuthorship W2741218617A5042433713 @default.
• W2741218617 hasAuthorship W2741218617A5047411615 @default.
• W2741218617 hasAuthorship W2741218617A5050945427 @default.
• W2741218617 hasAuthorship W2741218617A5058720085 @default.
• W2741218617 hasAuthorship W2741218617A5080254894 @default.
• W2741218617 hasAuthorship W2741218617A5086263266 @default.
• W2741218617 hasAuthorship W2741218617A5089196838 @default.
• W2741218617 hasBestOaLocation W27412186171 @default.
• W2741218617 hasConcept C112705442 @default.
• W2741218617 hasConcept C126322002 @default.
• W2741218617 hasConcept C142724271 @default.
• W2741218617 hasConcept C204787440 @default.
• W2741218617 hasConcept C27081682 @default.
• W2741218617 hasConcept C2776694085 @default.
• W2741218617 hasConcept C2777389519 @default.
• W2741218617 hasConcept C42404028 @default.
• W2741218617 hasConcept C44249647 @default.
• W2741218617 hasConcept C71924100 @default.
• W2741218617 hasConcept C76318530 @default.
• W2741218617 hasConcept C87813604 @default.
• W2741218617 hasConcept C90924648 @default.
• W2741218617 hasConcept C98274493 @default.
• W2741218617 hasConceptScore W2741218617C112705442 @default.
• W2741218617 hasConceptScore W2741218617C126322002 @default.
• W2741218617 hasConceptScore W2741218617C142724271 @default.
• W2741218617 hasConceptScore W2741218617C204787440 @default.
• W2741218617 hasConceptScore W2741218617C27081682 @default.
• W2741218617 hasConceptScore W2741218617C2776694085 @default.
• W2741218617 hasConceptScore W2741218617C2777389519 @default.
• W2741218617 hasConceptScore W2741218617C42404028 @default.
• W2741218617 hasConceptScore W2741218617C44249647 @default.
• W2741218617 hasConceptScore W2741218617C71924100 @default.
• W2741218617 hasConceptScore W2741218617C76318530 @default.
• W2741218617 hasConceptScore W2741218617C87813604 @default.
• W2741218617 hasConceptScore W2741218617C90924648 @default.
• W2741218617 hasConceptScore W2741218617C98274493 @default.
• W2741218617 hasIssue "3" @default.
• W2741218617 hasLocation W27412186171 @default.
• W2741218617 hasLocation W27412186172 @default.
• W2741218617 hasLocation W27412186173 @default.
• W2741218617 hasLocation W27412186174 @default.
• W2741218617 hasOpenAccess W2741218617 @default.
• W2741218617 hasPrimaryLocation W27412186171 @default.
• W2741218617 hasRelatedWork W1986616381 @default.
• W2741218617 hasRelatedWork W2013847231 @default.
• W2741218617 hasRelatedWork W2033685750 @default.
• W2741218617 hasRelatedWork W2050557946 @default.
• W2741218617 hasRelatedWork W2053536280 @default.
• W2741218617 hasRelatedWork W2055974197 @default.
• W2741218617 hasRelatedWork W2061638403 @default.
• W2741218617 hasRelatedWork W2091435156 @default.
• W2741218617 hasRelatedWork W2913025776 @default.
• W2741218617 hasRelatedWork W3145656073 @default.
• W2741218617 hasVolume "17" @default.
• W2741218617 isParatext "false" @default.
• W2741218617 isRetracted "false" @default.
• W2741218617 magId "2741218617" @default.
• W2741218617 workType "article" @default.